Pathios Therapeutics: Pioneering Cancer Immunotherapy

Pathios Therapeutics, a UK-based biotech company, secured a hefty $25 million in Series B funding to propel their groundbreaking immunotherapy approach. Backed by big names like Bristol Myers Squibb, Pathios aims to target GPR65, a genetic marker linked to various immune-related diseases. Led by industry veterans Tom McCarthy and Stuart Hughes, Pathios is on a mission to revolutionize cancer treatment by inhibiting GPR65 and reprogramming immune cells to fight tumors. With a team of seasoned professionals, Pathios is at the forefront of translating cutting-edge science into life-saving medicines.